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SUMMARY
Aims: Prophylactic oral N-acetylcysteine (NAC) has been widely used for prevention of
contrast-induced nephropathy (CIN). However, clinical studies have not been demonstrat-
ing this effect consistently because of evidence that NAC can alter serum creatinine levels
without affecting glomerular filtration rate (GFR). We investigated NAC for the prevention
of CIN by monitoring creatinine and cystatin C.
Methods: We enrolled 113 patients (49 patients in NAC group and 64 patients in control
group) with normal to subnormal GFR who were scheduled for cardiovascular procedures.
Patients in NAC group receive acetylcysteine 600 mg twice a day, on the day before and
on the day of cardiovascular procedure. All patients received a periprocedural intravenous
infusion (”volume expansion”) of 1 ml/kg/h with 0.45% saline for 24 h (12 h before and 12
h after exposure to contrast medium). Serum cystatin C and creatinine levels were measured
before and at 12, 24, and 48 h after procedure.
Results: The incidence of cystatin C-based CIN was 28.5% (n = 14) in NAC and 23.4%
(n = 15) in control group (p = 0.663) and serum creatinine-based CIN was 12.2% (n = 6)
in NAC and 17.2% (n = 11) in control group (P = 0.468). In this study, oral NAC had no
effect on the prevention of CIN in patients undergoing cardiovascular procedures.
Conclusion: In this study, oral NAC administration does not reduce neither the incidence of
cystatin C-based CIN nor serum creatinine-based CIN in patients undergoing cardiovascular
procedures.
Introduction
Continuous growth in diagnostic and interventional procedures
requires the use of radiographic contrast agents, which has led to
a parallel increase in the incidence of contrast-induced nephropa-
thy (CIN). CIN is third, the most common cause of hospital ac-
quired renal failure [1]. Most commonly, it is defined as a change
in serum creatinine over baseline by 48 h, such as ≥25% above
baseline or an absolute increase in the serum creatinine level of
at least 0.5 mg/dL [2]. Early studies showed that preexisting re-
nal impairment, age, anemia, diabetes, congestive heart failure,
shock, contrast volume, and osmolality were risk markers for the
development of acute deterioration in renal function after contrast
medium (CM) administration [3,4].
Although the pathogenesis of CIN in humans is not clear, it is
known that reactive oxygen species and renal ischemia play a role
in its development [5,6]. N-acetylcysteine (NAC) has the potential
to reduce the nephrotoxicity of CMs through antioxidant and va-
sodilatory effects [7]. Despite the large number of available data,
the true benefit of NAC is still unclear [8–10].
Glomerular filtration rate (GFR) is the accepted method for de-
tecting changes of renal function in patients receiving CM. As a
breakdown product of muscle, however, serum creatinine concen-
tration is influenced by a variety of nonrenal factors, including age,
gender, body weight, and protein intake. Furthermore, creatinine
is insensitive for detecting reductions in kidney function, which
may deteriorate more than 50% before serum creatinine exceeds
the normal range [11,12].
Serum cystatin C concentration, a new endogenous marker of
renal function, is believed to be superior to plasma creatinine
concentration as an indicator of renal function [13–15]. Cystatin
C is a low molecular weight (13 kDa) protein with 120 amino
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acids that functions as cysteine protease inhibitor. The protein is
freely filtered through the glomerulus and almost completely re-
absorbed and catabolized by tubular cells has been proposed as a
simple, reliable, and accurate marker of GFR [16]. Thus, the serum
concentration of cystatin C—in contrast with plasma creatinine
concentrations—does not depend on age, sex, and muscle mass
[17,18].
Materials and Methods
Study Population
Patients with normal to subnormal GFR and older than 18 years
of age, who were scheduled for elective cardiovascular procedures,
were eligible for this study. The exclusion criteria were accepted as
patients with uncontrolled hypertension, serum creatinine levels
of more than 7 mg/dL, severe valvular heart disease, preexisting
dialysis, autoimmune disease, chronic or acute infectious disease,
emergency catheterization, recent exposure to radiographic con-
trast within 10 days, medication with NSAID or metformin up to
3 days before entering study, allergy to radiographic contrast or
NAC.
The institutional ethics committee approved the study. In-
formed consent was obtained from each subject included to the
study.
Study Treatment
The patients were assigned to either the acetylcysteine group (NAC
group, n = 49) or the control group (n = 64). Patients in NAC
group receive acetylcysteine 600 mg twice a day, on the day before
and on the day of cardiovascular procedure. All patients received
a periprocedural intravenous infusion (”volume expansion”) of 1
mL/kg/h with 0.45% saline for 24 h (12 h before and 12 h after
exposure to CM). Estimated GFR was calculated by applying the
level-modified Modification of Diet in Renal Disease (MDRD) for-
mula: (186.3 × serum creatinine –1.154) × (age–0.203) × (0.742
if female) [19]. Serum cystatin C and creatinine levels were mea-
sured before and at 12, 24, and 48 h after procedure. Serum cre-
atinine was measured by the standard laboratory method. Serum
cystatin C was determined by sandwich enzyme immunoassay us-
ing a kit (Abnova, Taiwan). Hemoglobin, fasting glucose, blood
pressure, ejection fraction, and carotid intima media thickness (c-
IMT) were studied on admission. We also estimated Mehran risk
score, reflecting the risk of contrast nephropathy before the pro-
cedure. Mehran risk score is calculated according to several risk
factors, including dose of contrast media, baseline creatinine clear-
ance, older age, hypotension, heart failure, anemia, and diabetes,
as well as the use of intra-aortic balloon pump [4].
Cardiovascular Procedures
The performance of angiography, ventriculography, angioplasty,
and coincident noncoronary angiography was left to the discre-
tion of the cardiologist. Cardiologists performing cardiovascular
procedures were blinded to the group assignments. A nonionic
low-osmolar contrast agent (Iomeron R© 350 [350 mg iodine/ mL]
Bracco S.p.A ve Patheon ITALIA S.p.A., Italy) containing iomeprol
was used in all patients.
Study Purpose
The primary purposes of the study were (1) to assess a reduc-
tion in the incidence of cystatin C-based CIN in the acetylcys-
teine group, as compared with the control group and (2) to assess
whether early changes in cystatin levels anticipate the occurrence
of CIN. Serum cystatin C-based CIN was defined as an increase in
the serum cystatin C concentration greater than 25% within 48 h
of contrast exposure. Serum creatinine-based CIN was defined as
an increase in serum creatinine concentration greater than 25%
within 48 h of contrast exposure. In studies in which creatinine
and cystatin C concentrations were compared, the same percent-
age change in concentrations of both markers was considered rep-
resentative of a significant decrease in renal function [17].
Statistical Analysis
The data are expressed as mean ± standard deviation for
continuous variables and as frequency (number [%]) for
categorical variables. Mean, standard deviation, 25, median
(50), and 75 percentiles of the continuous variables were
given. The normality of data distribution was tested with the
Shapiro–Wilk and Kolmogorov–Smirnov tests. The Student t-test
and Mann–Whitney U test were used to determine differences
between mean values for normally and nonnormally distributed
variables, respectively. χ2 test was used for the comparison of
categorical variables. The repeated measures of ANOVA test was
done to assess the serial changes of serum cystatin C and creati-
nine concentration. ROC analysis was used to test predict opaque
nephropathy according to the changes in serum cystatin C after
contrast exposure. Data were analyzed using SPSS for Windows,
version 15 (Chicago, IL, USA), and P values <0.05 were consid-
ered statistically significant.
Results
We compared 49 patients receiving NAC with 64 patients in con-
trol group. The mean age of study population was 61.6 ± 9.6 years
old and men were 75 (66.4%) patients. The prevalence of diabetes
was 24.8%.
Of the 113 procedures, 96 were diagnostic angiographies and
17 were interventional procedures. Characteristics for the study
patients are shown in Table 1. The two groups of patients were
similar for age, sex, body mass index, systolic BP, diastolic BP, di-
abetes, baseline renal function tests (creatinine, estimated GFR-
MDRD, and cystatin C), and Mehran risk score. The volume of
contrast was not significantly different between the groups.
Baseline and post procedural 12, 24, and 48 h creatinin and
cystatin C levels are shown in Table 2.
There was no difference between two groups in regard of base-
line and postprocedural creatinine and cystatin levels.
The overall incidence of cystatin C-based CIN among all study
subjects was 25.6% (28.5% in NAC group and 23.4% in control
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Table 1 Baseline characteristics of the study subjects
NAC (n = 49) Control group (n = 64) P value
Age (years) 62.73 ± 9.62 60.84 ± 9.54 NS
Men (%) 67.3 65.6 NS
Systolic BP (mm Hg) 130.33 ± 18.86 130.23 ± 19.13 NS
Diastolic BP (mm Hg) 79.69 ± 10.46 77.58 ± 10.19 NS
DM (%) 22.4 26.5 NS
BMI (kg/m2) 27.41 ± 4.15 28.12 ± 3.93 NS
Volume of contrast agent (mL) 81.73 ± 48.82 97.89 ± 80.91 NS
Volume of contrast agent/BMI 3.06 ± 1.93 3.52 ± 3.18 NS
Mehran risk score 2.63 ± 2.47 2.46 ± 2.16 NS
Hemoglobin (g/dL) 13.26 ± 1.49 13.51 ± 1.73 NS
GFR (MDRD) (mL/min) 78.31 ± 20.56 83.56 ± 18.72 NS
LVEF (%) 51.79 ± 8.51 51.33 ± 10.21 NS
cIMT (mm) 1.04 ± 0.13 1.04 ± 0.12 NS
Data are expressed as mean ± SD and parenthesis number means percentage.
Abbrevations: DM, diabetes mellitus; BMI, body mass index; LVEF, left ventricular ejection fraction; GFR (MDRD), glomerular filtration rate (Modification of
Diet in Renal Disease); cIMT, carotid intima media thickness.
Table 2 Serial changes of creatinine and cystatin in each group
NAC (n = 49) Control group (n = 64) P value
Baseline creatinine (mg/dL) 0.91 ± 0.25 0.83 ± 0.17 NS
Creatinine at 12 h (mg/dL) 0.92 ± 0,27 0.84 ± 0.17 NS
Creatinine at 24 h (mg/dL) 1.01 ± 0.33 0.91 ± 0.19 NS
Creatinine at 48 h (mg/dL) 0.99 ± 0.33 0.92 ± 0.18 NS
Baseline cystatin C (ng/ml) 1425.89 ± 344.84 1449.51 ± 468.34 NS
Cystatin at 12 h (ng/ml) 1432.05 ± 482.45 1490.88 ± 618.91 NS
Cystatin at 24 h (ng/mL) 1547.91 ± 531.07 1506.65 ± 423.43 NS
Cystatin at 48 h (ng/mL) 1699.61 ± 521.67 1548.73 ± 475.36 NS
group, P = 0.663) and that of serum creatinine-based CIN was
15.0% (12.2% in NAC group and 17.2% in control group, P =
0.468). No patient with development of CIN required dialysis.
There was no adverse effect related to NAC treatment.
GFR was calculated according to their serum creatinin and
cystatin value at baseline, 12, 24, and 48 h after intervention.
Cokcroft–Gault (CG) and HOEK formula were used for GFR es-
timation. Repetitive values for GFR were tested with ANOVA for
each time series. The important finding revealed from the ANOVA
test is early decline in serum cystatin at 12 and 24 h imply with
the later creatinine increase at 48 h. In addition supports the find-
ing is patients with CIN had greater decrease in serum cystatin at
first 12 h compared to the baseline. The other analysis was done
according to their postprocedural serum creatinin value. Patients
classified according to their creatinin increase after intravenous
opaque administration as 15%, 25%, 35%, and 45% regardless
from their cysteine value (Figure 1A–D). More prominent crea-
tinin increase can be predictable with early cystatin decrease. Pa-
tient with lower serum cystatin levels compared to the baseline at
12 and 24 h have higher incidence of CIN at 48th hours. There was
a correlation between cystatin value at 12 and 24th hour’s (r =
0.384, P: 0.0001). Fifteen percent or more creatinin increase can
be predictable with cystatin decrease r = –0.341, P: 0.006 (Figure
1A–D). More than 15% increase in creatinin value is predictable
with 39% decrease in cystatin serum value at 12 h, compared to
baseline with 94% sensitivity (AUC 0.352; 0.013) in the ROC anal-
ysis (Figure 2).
Discussion
Our study shows that orally NAC administration does not
reduce neither the incidence of cystatin C-based CIN nor
serum creatinine-based CIN in patients undergoing cardiovascular
procedures.
CIN, a major cause of hospital-acquired renal failure, is associ-
ated with prolonged hospitalization and increased morbidity and
mortality [20]. Among all procedures utilizing CM for diagnostic
or therapeutic purposes, cardiovascular procedures are associated
with the highest rates of CIN [21]. CIN has been reported to occur
in 11–44% of patients with moderate renal insufficiency [1]. Risk
factors for CIN include preexisting renal failure (especially diabetic
nephropathy and multiple myeloma), hypovolemia, administra-
tion of (cumulative) high doses of (hyperosmolar) contrast media,
and concomitant use of nephrotoxic drugs [22,23].
Although serum creatinine is widely used as such a marker, it
should be kept in mind that it is influenced by age, gender, muscle
mass, and protein intake, and that it shows low sensitivity for the
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Figure 1 (A) The repeatedmeasures of ANOVA test. Cystatin levels at base-
line, 12, 24, and 48 h are shown with 1, 2, 3, 4 in patients with or without
creatinine increased more than 15%. Creatinine level increased more than
15% at 48 h is shown with blue color and creatinine clearance increased
more than 15% is shown with green color. (B) The repeated measures of
ANOVA test. Cystatin levels at baseline, 12, 24, and 48 h are shown with
1, 2, 3, 4 in patients with or without creatinine increased more than 25%.
Creatinine clearance increased more than 25% is shown with green color.
(C) The repeated measures of ANOVA test. Cystatin levels at baseline, 12,
24, and 48 h are shown with 1, 2, 3, 4 in patients with or without creatinine
increased more than 35%. Creatinine clearance increased more than 35% is
shownwith green color. (D) The repeatedmeasures of ANOVA test. Cystatin
levels at baseline, 12, 24, and 48 h are shown with 1, 2, 3, 4 in patients
with or without creatinine increased more than 45%. Creatinine clearance
increased more than 45% is shown with green color.
detection of early renal dysfunction [24,25]. Cystatin C is a 13 kD
endogenous cysteine proteinase inhibitor and is produced by nu-
cleated cells at a constant rate. Cystatin C is freely filtered by the
glomerulus, reabsorbed, and catabolized, but it is not secreted by
the tubules [26,27]. Many studies have demonstrated the superi-
ority of serum cystatin C for detecting early renal impairment than
creatinine and creatinine clearance calculated by the CG formula
or the MDRD [27,28].
NAC is the most studied prophylaxis agent to date. The mech-
anism of action by which it exerts its nephroprotective effects is
unknown but it is postulated to act as a free-radical scavenger.
In an initial trial, Tepel et al. demonstrated protective effect of
NAC (600 mg twice daily on the day before and the day of the
scan) in CIN [5]. Since that seminal study there have been many
published studies with great heterogeneity in results, some finding
substantial benefit for NAC, others reporting no effect. Possible ex-
planations for these contrasting results are differences in applied
hydration regimens, in the patient populations studied and in the
volumes of contrast media administered, and variations in the
timing and dosing of NAC. Also efficacy of NAC is controversial
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Figure 2. ROC analysis. Sensitivity of relationship between decline in cys-
tatin 0–12 h as a percentage and increase in creatinine more than 15% was
calculated AUC 0.352, P = 0.013.
because of evidence that NAC can alter serum creatinine levels
without affecting GFR. Therefore, cystatin C seems to be more sen-
sitive than creatinine for evaluation of the renoprotective role of
NAC after administration of CM. However, there is a little data
available on the effect of NAC on the development of cystatin C-
based CIN after CM exposure. Poletti et al. randomly assigned 87
patients with renal insufficiency that underwent emergency com-
puted tomography (CT) to NAC and hydration (900 mg injection
of NAC 1 h before and another immediately after injection of CM)
or only hydration. Average contrast administered was 126 ± 22
mL in NAC group and 125 ± 24 mL in control group. Nine of 43
(21%) patients in the control group and 2 of 44 (5%) patients in
NAC group had serum creatinine based CIN (P = 0.026). Nine of
40 (22%) patients in the control group and 7 of 41 (17%) patients
in NAC group had cystatin-C based CIN (P = 0.59). The authors
demonstrated renoprotective effect of IV NAC against CIN accord-
ing to serum creatinine, but did not demonstrate similar effect ac-
cording to serum cystatin C based CIN [29]. Kim et al. enrolled 166
patients with apparently normal renal function that underwent
elective coronary angiography to NAC (oral acetylcysteine at 600
mg twice a day, on the day before and on the day of coronary an-
giography) or placebo. Average contrast administered was 201 ±
44 mL in NAC group and 216 ± 166 mL in control group. The
overall incidence of cystatin C-based CIN among all study subjects
was 10.2% (5.0% in NAC group and 15.1% in control group, P =
0.05) and that of serum creatinine-based CIN was 6% (3.8% in
NAC group and 8.1% in control group, P = NS). These investiga-
tors concluded that NAC prevented cystatin based CIN and serum
cystatin C more sensitive marker of the early CIN than serum cre-
atinine [30].
Kimmel et al. randomly assigned 54 patients with moderately
impaired kidney function to an oral treatment for 2 days with 1.2
g/day of NAC, for 1 day with 60 mg/day of Zn or placebo. Average
of CM volumes were 219 ± 105 mL in control group, 187 ± 88 mL
in NAC group, and 173 ± 85 mL in Zinc group (P = NS). In this
study authors showed that NAC has no effect in preventing CIN by
the standard definition, but based on cystatin C they can confirm
a preventive effect of NAC [31]. Two of these trials demonstrated
preventive effect of NAC based on cystatin C assessment. The vol-
umes of CM in these studies were considerably greater [30,31]. In
the study by Kim et al. overall incidence of CIN was lower than in
the other two trials. It would be explained by differences in study
design. Kim et al. enrolled patients with normal renal function. In
the study by Poletti et al. intravenous protocol of NAC was used.
In the other two trials oral treatment of 1200 mg NAC was pre-
ferred. The dose of oral NAC in our study was similar to previous
studies.
The purpose of our study was to evaluate the renoprotective ef-
fect of NAC in patients with normal to subnormal function who
underwent elective cardiovascular procedures. We first analyzed
changes in serum creatinine and cystatin C concentrations in NAC
and control groups at baseline, 12, 24, and 48 h after proce-
dure. The overall incidence of cystatin C-based CIN among all
study subjects was higher, but not significantly higher, than serum
creatinine-based CIN. This is explained as serum cystatin C levels
have been reported to be a more sensitive to detect early changes
in renal impairment than serum creatinine levels [32,33]. In this
study, we observed that early (12 and 24 h) decline in cystatin
level predict CIN at 48 h. In our study average of CM volume was
90.8 ± 69.1 mL, because in high-risk patients we avoided left ven-
triculography. The volume of contrast used in three of the studies
was higher than used in our study [31–33]. The administration of
fluids is the cornerstone treatment to reduce the risk of CIN. Al-
though the optimal hydration strategy is uncertain, available data
support a regimen of 0.9% saline at 1 mL/kg/h intravenously for
12 h before administration of the CM and continuing for up to
12 h after [34]. The hydration protocol used in our study was the
same as that used in previous studies (1 mL/kg/h for 12 h before
and 12 h after procedure) [30,31].
Our study shows that in patients with normal to subnormal
GFR, prophylactic oral NAC administration is ineffective at pre-
venting either cystatin C-based CIN or serum creatinine based CIN
development after elective cardiovascular procedures. The inef-
ficacy of NAC therapy may be due to several factors, including
the presence of adequate saline infusion, normal renal function,
and low opaque volume. The second observation of our study that
early decline in cystatin level may predict CIN at 48 h.
Study Limitations
In this study, the patients were observed for only 12–48 h. We can-
not exclude the possibility that an earlier change (first 6 h) may
occur. Also it is possible that changes in renal function could have
occurred after 48 h, and consequently, the measuring of the renal
function test within 48 h after the procedure may cause underes-
timation of the nephropathy risk.
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